Everence Capital Management Inc. Takes Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Everence Capital Management Inc. acquired a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 4th quarter, Holdings Channel.com reports. The firm acquired 9,020 shares of the medical device company’s stock, valued at approximately $267,000.

Several other institutional investors have also modified their holdings of TNDM. JPMorgan Chase & Co. lifted its holdings in shares of Tandem Diabetes Care by 40.5% during the 1st quarter. JPMorgan Chase & Co. now owns 133,397 shares of the medical device company’s stock valued at $15,512,000 after purchasing an additional 38,460 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of Tandem Diabetes Care by 2.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 6,246 shares of the medical device company’s stock valued at $726,000 after purchasing an additional 164 shares in the last quarter. Great West Life Assurance Co. Can lifted its holdings in shares of Tandem Diabetes Care by 7.5% during the 1st quarter. Great West Life Assurance Co. Can now owns 34,482 shares of the medical device company’s stock valued at $4,122,000 after purchasing an additional 2,402 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Tandem Diabetes Care by 68.5% during the 1st quarter. Dimensional Fund Advisors LP now owns 185,408 shares of the medical device company’s stock valued at $21,561,000 after purchasing an additional 75,358 shares in the last quarter. Finally, Canada Pension Plan Investment Board raised its position in Tandem Diabetes Care by 3.4% in the 1st quarter. Canada Pension Plan Investment Board now owns 5,616 shares of the medical device company’s stock valued at $654,000 after buying an additional 184 shares during the last quarter.

Analyst Upgrades and Downgrades

TNDM has been the topic of a number of recent research reports. Citigroup lifted their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. Stifel Nicolaus raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and lifted their target price for the company from $24.00 to $37.00 in a research report on Tuesday, March 26th. Finally, StockNews.com raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $37.00.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM opened at $30.93 on Friday. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $41.22. The stock’s 50 day moving average price is $29.64 and its two-hundred day moving average price is $24.76. The company has a quick ratio of 3.02, a current ratio of 3.83 and a debt-to-equity ratio of 0.91.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to analyst estimates of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. Analysts predict that Tandem Diabetes Care, Inc. will post -1.62 EPS for the current year.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.